How common is pancreatitis with Mounjaro, and what should you watch for?

How often does pancreatitis actually appear in the Mounjaro trials?

The short answer: rarely. Across the SURMOUNT clinical programme, acute pancreatitis was reported in a small proportion of participants (typically under 1%) and the rates were broadly in line with what is seen in people living with obesity regardless of treatment. The NHS medicines page for tirzepatide lists pancreatitis as an uncommon side effect, meaning it is estimated to affect fewer than 1 in 100 people.

That framing matters. It is uncommon, not rare in the way a bolt of lightning is rare, but it is far less likely than the nausea and loose stools that many people notice in the first few weeks. A common misconception is that GLP-1 medicines routinely cause pancreatitis; the data do not support that. What the data do support is that the risk exists and should be taken seriously, particularly for people who already have risk factors for the condition such as gallstones, heavy alcohol use, or very high triglycerides.

If you want to explore the full picture of how pancreatitis compares to other Mounjaro side effects, that page covers the complete profile. And for a closer look at the biological relationship between tirzepatide and the pancreas, our page on whether Mounjaro can cause pancreatitis goes into the mechanism in more detail.

The January 2026 MHRA warning, and what it means for you

In January 2026, the MHRA published a Drug Safety Update for all GLP-1 receptor agonists, including Mounjaro, drawing attention to acute pancreatitis as a known and potentially serious risk. This was not a surprise finding (pancreatitis had already appeared in the prescribing information) but the regulator judged it important enough to communicate directly to prescribers and patients. You can report a suspected side effect, including any pancreatitis episode you think may be linked to your treatment, through the MHRA Yellow Card scheme.

The update reinforced existing guidance: people should stop taking Mounjaro if pancreatitis is confirmed, and should not restart it without specialist advice. The signal also underlines why prescribers ask about your history with pancreatitis before approving treatment. If you've had it before, that information is clinically relevant, not a reason to feel embarrassed at consultation, but a fact that helps a prescriber weigh your individual risk properly.

For a detailed breakdown of the risk of pancreatitis with Mounjaro, including what factors raise it and what the comparative rates look like, that page covers the evidence in full.

When to get medical help, and when to call 999

The symptom to know is straightforward: severe pain in your stomach or abdomen that does not ease off, often spreading through to your back, sometimes with vomiting. This is the classic presentation of acute pancreatitis. It is different from the usual Mounjaro nausea, which tends to be milder, comes in waves, and does not typically radiate to the back.

If you develop pain that fits this pattern, seek medical help the same day, do not wait for your next injection day or for it to pass on its own. In the UK, you can call 111 for urgent non-emergency advice, or go directly to A&E if the pain is severe. Stop your Mounjaro dose until you have spoken to a clinician.

Our page on Mounjaro and pancreatitis covers what to do step by step. And if you are already partway through treatment and wondering whether your symptoms are related, this page on taking Mounjaro with a history of pancreatitis addresses that specific situation. For practical steps on reducing your risk day to day, see our guide on how to avoid pancreatitis on Mounjaro.

How prescribers weigh this risk before and during treatment

At consultation, your prescriber is not just ticking eligibility boxes. They are looking at the full picture: your BMI, your weight-related conditions, your medication list, and your personal history with things like gallstones or prior abdominal surgery, all of which can affect pancreatic risk. That is part of why a clinical assessment is required for a prescription-only medicine like Mounjaro, and why a prescriber who has read your answers properly is the right person to have this conversation with.

If Mounjaro is approved as suitable for you, your prescriber can also talk through what to watch for in the early weeks of treatment, including how to tell a pancreatitis warning sign apart from ordinary GI discomfort. At nume, that conversation happens before your first pen is dispatched, and our prescribers are available for aftercare questions seven days a week. If you'd like to understand the eligibility criteria and what the consultation involves before starting, the Mounjaro overview page covers that in plain terms.

Treatment decisions are personal and should be made with clinical support. If you'd like to explore whether Mounjaro is suitable for you, speak to our prescribers as part of a free consultation.